U.S. Pharmaceuticals & Biotech Breakout Stocks

Maravai LifeSciences Holdings

Market Cap: US$2.3b

A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.

Inhibrx Biosciences

Market Cap: US$1.8b

A clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

Pacific Biosciences of California

Market Cap: US$472.5m

Designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Cypherpunk Technologies

Market Cap: US$176.7m

A privacy technology company, implements a digital asset strategy anchored by Zcash in the United States.

Rafael Holdings

Market Cap: US$116.5m

Primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.

BioVie

Market Cap: US$15.8m

A clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.

Eastgate Biotech

Market Cap: US$3.2m

A development stage company, develops novel formulations of natural compounds and pharmaceutical products.

Emmaus Life Sciences

Market Cap: US$2.7m

A commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.

Manhattan Scientifics

Market Cap: US$559.0

A technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States.